Health
Semaglutide Shows Promise in Treating Serious Liver Condition, New Study Finds
A widely used ingredient in popular weight-loss drugs has shown promising results in treating a progressive liver condition for which no medications are currently approved in the European Union, according to a major new study published in the New England Journal of Medicine.
The clinical trial, funded by Danish pharmaceutical giant Novo Nordisk, found that semaglutide – the active compound in the blockbuster drugs Ozempic and Wegovy – significantly improved outcomes for patients suffering from metabolic dysfunction-associated steatohepatitis (MASH). The disease, which causes fat accumulation, inflammation, and scarring in the liver, is associated with obesity, type 2 diabetes, and high blood pressure and can progress to cirrhosis if left untreated.
The 72-week trial involved 800 participants with MASH and moderate to advanced liver fibrosis. Patients who received weekly injections of semaglutide showed notable improvements, with 33 percent experiencing reductions in both liver inflammation and scarring, compared to just 16 percent in the placebo group. Separately, 63 percent saw a decrease in liver inflammation, and 37 percent showed improved scarring. The placebo group showed improvements of 34 percent and 22 percent, respectively.
Participants taking semaglutide also lost an average of 10.5 percent of their body weight, reinforcing the drug’s potential dual benefit in treating both liver disease and obesity-related complications.
Professor Debbie Shawcross, a liver specialist at King’s College London and vice secretary general of the European Association for the Study of the Liver, called the findings “hugely exciting,” but cautioned that semaglutide alone may not be responsible for all the improvements. Participants across both treatment arms received lifestyle counseling and support in managing related health conditions, suggesting that behavior changes also played a significant role.
“This is important as any therapy that is licensed for MASH with moderate to severe fibrosis must be used in conjunction with lifestyle interventions,” Shawcross noted.
While semaglutide showed promise, some patients reported gastrointestinal side effects, including nausea, vomiting, and diarrhea. Around 2.6 percent of those on the drug withdrew from the study due to adverse effects.
Novo Nordisk, which announced the trial’s topline results in late 2024, has stated it plans to seek regulatory approval for semaglutide as a MASH treatment in both the EU and US by mid-2025. If approved, it would become the first such therapy available in Europe.
The move comes as the EU is also reviewing other experimental treatments for MASH, including resmetirom, which was approved in the US last year after showing positive results in reducing liver scarring.
While Shawcross said it is “too early to call” semaglutide a game-changer, she emphasized its potential if used alongside comprehensive lifestyle programs. However, she warned that many patients taking weight-loss drugs do not make lasting changes, raising concerns about the long-term impact once the medication is stopped.
Health
Global Mental Health Cases Near 1.2 Billion as Anxiety and Depression Drive Sharp Worldwide Rise
A major global analysis has found that mental health conditions have surged to an estimated 1.2 billion people worldwide, driven largely by steep increases in anxiety and depression over the past three decades.
The findings, published in The Lancet as part of the Global Burden of Disease Study 2023, show that the number of people living with mental disorders has almost doubled since 1990, marking a 95% rise. Researchers say major depressive disorder and anxiety disorders have seen even sharper growth, increasing by 131% and 158% respectively, making them the most prevalent mental health conditions globally.
The report describes mental illnesses as widespread conditions that create long-term disability and significant human suffering. It also highlights broader consequences for economies and public services, including reduced productivity, lower workforce participation and increasing pressure on health and welfare systems.
Researchers estimate that in 2023 alone, around 620 million females and 552 million males were affected by mental health conditions. While the overall burden is rising across both sexes, the study points to notable differences in the types and prevalence of disorders.
Among women, depression and anxiety were the most commonly reported conditions, alongside higher rates of eating disorders such as anorexia nervosa and bulimia nervosa. The report links this disparity to a mix of biological, social and structural factors, including exposure to domestic violence, sexual abuse, gender inequality and reproductive health-related changes.
In contrast, neurodevelopmental and behavioural disorders, including attention deficit hyperactivity disorder (ADHD), conduct disorder and autism spectrum conditions, were more frequently diagnosed in men.
Teenagers aged 15 to 19 were identified as the group experiencing the highest mental health burden globally, raising concerns about early onset of conditions and insufficient preventive care for young people.
The study identifies several key risk factors associated with mental illness, including childhood sexual violence, bullying and intimate partner violence. These factors are strongly linked to conditions such as depression, schizophrenia, bipolar disorder and anxiety disorders. However, researchers note that such exposures have remained relatively stable over time and account for only a portion of the overall rise.
According to the authors, broader drivers are likely contributing to the increasing prevalence of mental disorders. These include genetic and biological influences, poverty, inequality, and the growing impact of global crises such as armed conflict, pandemics, natural disasters and climate-related stress.
While mental health conditions have long been a leading cause of disability worldwide, the report warns that the situation is worsening. At the same time, health systems have not expanded services at a pace matching demand.
The authors caution that the gap between rising need and limited access to care is becoming more pronounced, leaving millions without adequate treatment or support.
Health
Europe Records Sharp Rise in Sexually Transmitted Infections, ECDC Warns
Health
White House Rejects Report It Blocked Return of Ebola-Infected US Doctor
-
Entertainment2 years agoMeta Acquires Tilda Swinton VR Doc ‘Impulse: Playing With Reality’
-
Sports2 years agoChina’s Historic Olympic Victory Sparks National Pride Amid Controversy
-
Business2 years agoSaudi Arabia’s Model for Sustainable Aviation Practices
-
Business2 years agoRecent Developments in Small Business Taxes
-
Home Improvement1 year agoEffective Drain Cleaning: A Key to a Healthy Plumbing System
-
Politics2 years agoWho was Ebrahim Raisi and his status in Iranian Politics?
-
Sports2 years agoKeely Hodgkinson Wins Britain’s First Athletics Gold at Paris Olympics in 800m
-
Business2 years agoCarrectly: Revolutionizing Car Care in Chicago
